Arcus Biosciences, Inc.

RCUS Healthcare Biotechnology

Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024. In the quarter to June 2026, revenue fell 74.4%, EPS was flat, free cash flow grew 10.5% and total debt rose 4.12%, each against the same quarter a year earlier.

22.12 0.70 −3.07%
Market cap
$2.9B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
0/9
Altman Z
1.11
Beneish M
−2.42
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
0 1 0 1

+8 more TTM periods

ROE
(90.82%) (69.95%) (63.26%) (68.13%)
ROA
(46.02%) (34.28%) (30.84%) (30.64%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(77.44%) (54.83%) (43.26%) (51.36%)
Average Days of Receivables
112.31 4.64 16.26 16.73
Free Cash Flow per Share
(3.76) (3.89) (4.51) (4.36)
Free Cash Flow
(474.00) (488.00) (484.00) (464.00)
Other line items

Show all line items

Columns are period end dates